ArriVent BioPharmaAVBP
AVBP
About: ArriVent BioPharma Inc is a clinical-stage biopharmaceutical company dedicated to the identification, development, and commercialization of differentiated medicines to address the unmet medical needs of patients with cancers. It seeks to utilize the team's deep drug development experience to maximize the potential of the lead development candidate, furmonertinib, and advance a pipeline of novel therapeutics, such as next-generation antibody-drug conjugates, through approval and commercialization in patients suffering from cancer, with an initial focus on solid tumors.
Employees: 52
0
Funds holding %
of 7,419 funds
0
Analysts bullish %
of 3 analysts
Fund manager confidence
Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)
209% more repeat investments, than reductions
Existing positions increased: 34 | Existing positions reduced: 11
140% more first-time investments, than exits
New positions opened: 24 | Existing positions closed: 10
24% more capital invested
Capital invested by funds: $612M [Q3] → $757M (+$145M) [Q4]
20% more funds holding in top 10
Funds holding in top 10: 5 [Q3] → 6 (+1) [Q4]
19% more funds holding
Funds holding: 67 [Q3] → 80 (+13) [Q4]
7.34% more ownership
Funds ownership: 77.13% [Q3] → 84.47% (+7.34%) [Q4]
Research analyst outlook
3 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$37
82%
upside
Avg. target
$40
99%
upside
High target
$45
122%
upside
3 analyst ratings
3 positive
100%
0 neutral
0%
0 negative
0%
B. Riley Securities Kalpit Patel 9% 1-year accuracy 1 / 11 met price target | 82%upside $37 | Buy Initiated | 20 Mar 2025 |
Guggenheim Michael Schmidt 26% 1-year accuracy 10 / 38 met price target | 122%upside $45 | Buy Initiated | 10 Mar 2025 |
HC Wainwright & Co. Robert Burns 15% 1-year accuracy 26 / 172 met price target | 92%upside $39 | Buy Reiterated | 7 Mar 2025 |
Financial journalist opinion
Neutral
GlobeNewsWire
1 month ago
ArriVent BioPharma Reports Full Year 2024 Financial Results
NEWTOWN SQUARE, Pa., March 03, 2025 (GLOBE NEWSWIRE) -- ArriVent BioPharma, Inc. (Company or ArriVent) (Nasdaq: AVBP), a clinical-stage company dedicated to accelerating the global development of innovative biopharmaceutical therapeutics, today reported financial results for the year ended December 31, 2024, and highlighted recent Company progress.
Neutral
GlobeNewsWire
3 months ago
ArriVent BioPharma Enters Exclusive License with Lepu Biopharma for MRG007, an Antibody Drug Conjugate for the treatment of Gastrointestinal Cancers
NEWTOWN SQUARE, Pa. and SHANGHAI, Jan. 21, 2025 (GLOBE NEWSWIRE) -- ArriVent BioPharma, Inc. (Company or ArriVent) (Nasdaq: AVBP) a clinical-stage company dedicated to accelerating the global development of innovative biopharmaceutical therapeutics, today announced that it has entered into an exclusive license agreement with Lepu Biopharma Co., Ltd (Stock Code: 02157.HK) for MRG007, an antibody-drug conjugate (ADC) that can target several gastrointestinal (GI) cancers. Under the terms of the agreement, ArriVent obtains the exclusive rights to develop and commercialize MRG007 worldwide outside of Greater China which includes mainland China, Hong Kong, Macau and Taiwan.
Positive
MarketBeat
5 months ago
Discover the 3 Best-Performing Biotech IPO Stocks of 2024
Biotech and pharmaceutical companies are well known for raising capital through initial public offerings, or IPOs. Between 2001 and 2023, approximately 24% of IPOs were from biotech and pharmaceutical companies.
Neutral
GlobeNewsWire
7 months ago
ArriVent Announces Positive Proof-Of-Concept Global Phase 1b Interim Data for Firmonertinib Monotherapy In First-Line EGFR PACC Mutant Non-Small Cell Lung Cancer At The 2024 World Conference On Lung Cancer
81.8% ORR by BICR and 63.6% confirmed ORR by BICR at the 240 mg dose; 46.2% confirmed ORR in CNS Metastases 90.9% (n = 20/22) of patients with confirmed responses remained on study with a median duration of response not yet reached at time of analysis ArriVent to host virtual webinar on these interim analyses of Phase 1b data for firmonertinib in EGFR PACC mutant NSCLC on September 9, 2024 at 4:30 pm ET NEWTOWN SQUARE, Pa., Sept. 09, 2024 (GLOBE NEWSWIRE) -- ArriVent BioPharma, Inc. (Company or ArriVent) (Nasdaq: AVBP), a clinical-stage company dedicated to accelerating the global development of innovative biopharmaceutical therapeutics, today announced positive proof-of-concept randomized global Phase 1b FURTHER interim data for first-line firmonertinib monotherapy in patients with non-small cell lung cancer (NSCLC) harboring EGFR PACC mutations at a Presidential Symposium Presentation at the IASCLC 2024 annual World Conference on Lung Cancer (WCLC), in San Diego, California.
Positive
Zacks Investment Research
8 months ago
Wall Street Analysts Think ArriVent BioPharma, Inc. (AVBP) Could Surge 27.26%: Read This Before Placing a Bet
The mean of analysts' price targets for ArriVent BioPharma, Inc. (AVBP) points to a 27.3% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Neutral
Business Wire
8 months ago
Aarvik Therapeutics Announces Option Exercise by Collaboration Partner ArriVent BioPharma
HAYWARD, Calif.--(BUSINESS WIRE)-- #biotechnology--Aarvik Therapeutics is pleased to announce that ArriVent BioPharma, Inc. has exercised the option to exclusively license the collaboration program.
Neutral
GlobeNewsWire
8 months ago
ArriVent BioPharma Reports Second Quarter 2024 Financial Results
Clinical proof-of-concept monotherapy data for once daily, first-line firmonertinib in EGFR PACC mutant non-small cell lung cancer (NSCLC) to be presented as a presidential symposium presentation at the 2024 World Conference on Lung Cancer (WCLC)
Neutral
GlobeNewsWire
8 months ago
ArriVent to Present Proof-Of-Concept Phase 1b Data for Firmonertinib in EGFR PACC Mutant Non-Small Cell Lung Cancer at the 2024 World Conference on Lung Cancer
First-line monotherapy data for once daily firmonertinib selected as an oral presentation in the presidential session
Neutral
GlobeNewsWire
10 months ago
ArriVent Announces a Multi-Target ADC Collaboration with Alphamab
Collaboration will leverage Alphamab's antibody drug conjugate (“ADC”) research and discovery platform and ArriVent's global development and commercialization expertise
Neutral
GlobeNewsWire
11 months ago
ArriVent Appoints John Hohneker, M.D., to its Board of Directors
NEWTON SQUARE, Pa., May 16, 2024 (GLOBE NEWSWIRE) -- ArriVent BioPharma, Inc., a clinical-stage company dedicated to accelerating the global development of innovative biopharmaceutical therapeutics, today announced the appointment of John Hohneker, M.D. to its Board of Directors. Dr. Hohneker brings over 30 years of experience in biopharmaceutical leadership and drug development, and currently serves on the Boards of public companies Carisma Therapeutics, Inc. and Curis, Inc., and private companies Sonata Therapeutics and Trishula Therapeutics.
Charts implemented using Lightweight Charts™